Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

2019618 citationsJournal Articlebronze Open Access

Authors

Takashi Yamamura · National Center of Neurology and Psychiatry

Ingo Kleiter · St. Josef-Hospital

Kazuo Fujihara · Southern Tohoku General Hospital

Jacqueline Palace · John Radcliffe Hospital

Benjamin Greenberg · The University of Texas Southwestern Medical Center

Beata Zakrzewska‐Pniewska · Medical University of Warsaw

Francesco Patti

Abstract

Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. (Funded by Chugai Pharmaceutical; ClinicalTrials.gov number, NCT02028884.).

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Long-Term Effects of COVID-19

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 22, pp. 2114-2124

DOI: 10.1056/nejmoa1901747

Field-Weighted Citation Impact: 44.98